VYGR at a glance
Voyager Therapeutics, Inc. (VYGR, SEC CIK 1640266) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 18, 2026 and Form 4 insider filings as recently as November 3, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Voyager Therapeutics, Inc. (VYGR) reported revenue of $40.4 million (down 49.5% from FY2024) and a net loss of $119.7 million. Diluted EPS was -$2.04.
- As of September 30, 2026, 26 institutional investment managers tracked by SignalX reported holding Voyager Therapeutics, Inc. (VYGR) shares worth $56.5 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $40.4M
- −49.5% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 26 funds
- $56.5M · +0 vs prior quarter
- Latest 8-K
- Nov 18, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Collaboration revenue $4.0M, down from $13.4M YoY, a $9.4M decrease
- Net loss $24.7M vs $27.9M YoY, operating expenses $30.4M vs $44.0M
- Best line: Novartis collaboration revenue $3.1M, worst: Neurocrine revenue $0.5M vs $11.1M YoY
- Operating cash use $78.9M through September, cash, equivalents and securities $132.1M
- Runway into Q2 2028, VY1706 dosing expected in coming months, acute safety data anticipated Q1 2027
Risk Factors
- No material risk-factor changes identified; filing references carried-forward 10-K risks
- Clinical development risk: VY1706 trial expected to enroll up to 18 patients across three cohorts
- Regulatory risk: FDA-cleared VY1706 IND, but clinical dosing remains subject to enrollment timing
- Collaboration concentration risk: nine-month collaboration revenue fell to $9.8 million from $25.0 million
- Liquidity risk: cash, cash equivalents and marketable securities totaled $132.1 million, expected to fund operations into second quarter 2028
AI summary of the VYGR 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item EX-99.1: Item EX-99.1
- Q3 collaboration revenue $4.0M, down from $13.4M, reflecting reduced Neurocrine revenue as programs move beyond research
- R&D expense $24.4M, down from $35.9M, while net loss narrowed to $24.7M from $27.9M
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results and corporate updates announced on November 5, 2026
- Full results and management commentary available in Exhibit 99.1, the accompanying press release
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results and corporate updates announced on November 5, 2026
- Full results and operating details provided in Exhibit 99.1 press release
Item EX-99.1: Item EX-99.1
- Q3 net loss $24.7M, or $0.40 per share, improved from $27.9M, or $0.47, despite collaboration revenue falling to $4.0M from $13.4M
- Cash, equivalents and marketable securities $132.1M at September 30, funding planned operations into Q2 2028
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Robin Swartz appointed President effective October 20, 2026, strengthening internal succession continuity
- Expected CEO transition after first-quarter 2027 VY1706 acute safety data, with Alfred Sandrock remaining on the Board
AI summaries of VYGR 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for VYGR
Don't miss the next VYGR filing
- Alerts as it files. A push when VYGR files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut VYGR, by share count.
- Ask anything. An AI agent that reads every VYGR filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Swartz Robin | A | Nov 1, 2026 | 318,500 | - |
| Swartz Robin | A | Nov 1, 2026 | 68,250 | - |
| Carter Todd Alfred | A | Nov 1, 2026 | 33,000 | - |
| Carter Todd Alfred | A | Nov 1, 2026 | 154,000 | - |
| Onyia Jude | A | Jun 9, 2026 | 30,000 | - |
| PIERCE GLENN | A | Jun 9, 2026 | 30,000 | - |
| Higgins Michael J | A | Jun 9, 2026 | 30,000 | - |
| Colon Grace | A | Jun 9, 2026 | 30,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $80.0M | $40.4M |
| Operating Income | - | -$83.3M | -$131.8M |
| Net Income | $132.3M | -$65.0M | -$119.7M |
| Op. Margin | - | -104.1% | -326.6% |
| Net Margin | - | -81.3% | -296.5% |
| Balance Sheet | |||
| Total Assets | $351.3M | $393.1M | $252.3M |
| Equity | - | $299.8M | $196.1M |
| ROE | - | -21.7% | -61.1% |
| Per Share | |||
| EPS | $2.97 | $-1.13 | $-2.04 |
| Cash Flow | |||
| Operating CF | - | -$15.3M | -$132.5M |
| CapEx | $3.3M | $3.5M | $2.6M |
Source: XBRL data in Voyager Therapeutics, Inc. (VYGR)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate VYGR share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 26 | $56.5M |
| Q2 2026 | 26 | $70.4M |
| Q1 2026 | 25 | $70.7M |
| Q4 2025 | 23 | $66.5M |
| Q3 2025 | 23 | $82.8M |
| Q2 2025 | 22 | $50.5M |
| Q1 2025 | 20 | $30.3M |
| Q4 2024 | 18 | $41.5M |
- BlackRock+1.60M (+31%)
- Millennium Management+435.3K (+10%)
- Goldman Sachs Group+234.8K (+69%)
- Morgan Stanley+45.7K (+7%)
- State Street Corp+19.7K (+2%)
- Citadel Advisors LLC−460.1K (-59%)
- AQR Capital Management−192.9K (-54%)
- Dimensional Fund Advisors−177.6K (-21%)
- D.E. Shaw & Co−125.0K (-87%)
- Two Sigma Investments−104.9K (-11%)
- Ameriprise Financial+52.6K
- FMR LLC (Fidelity)−175.9K
Source: 13F-HR filings on SEC EDGAR (aggregated from 183 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
VYGR filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 18, 2026 | - | Analysis | - |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Nov 3, 2026 | - | - | - |
| 4 | Nov 3, 2026 | - | - | - |
| 8-K | Oct 21, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 8-K | Jul 13, 2026 | - | Analysis | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 8-K | Jun 10, 2026 | - | Analysis | |
| 8-K | Jun 1, 2026 | - | Analysis | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 7, 2026 | - | Analysis | |
| 8-K | Apr 21, 2026 | - | Analysis | - |
| 4 | Apr 3, 2026 | - | - | - |
| 4 | Apr 3, 2026 | - | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
VYGR SEC filings: frequently asked questions
Which institutions hold VYGR stock?
As of September 30, 2026, the largest Voyager Therapeutics, Inc. (VYGR) holders among the 13F filers tracked by SignalX were BlackRock ($18.1 million), Millennium Management ($13.1 million), Vanguard Capital Management LLC ($6.3 million), State Street Corp ($2.9 million), Two Sigma Investments ($2.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was VYGR's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Voyager Therapeutics, Inc. (VYGR) reported revenue of $40.4 million (down 49.5% from FY2024) and a net loss of $119.7 million. Diluted EPS was -$2.04. The figures come from the XBRL data in the 10-K.
What did VYGR report in its latest 8-K?
Voyager Therapeutics, Inc. (VYGR) filed an 8-K on November 18, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 collaboration revenue $4.0M, down from $13.4M, reflecting reduced Neurocrine revenue as programs move beyond research.
What are the latest VYGR SEC filings?
Voyager Therapeutics, Inc. (VYGR) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 18, 2026 and a Form 4 insider filing on November 3, 2026.
What is VYGR's SEC CIK number?
Voyager Therapeutics, Inc. (VYGR)'s SEC Central Index Key (CIK) is 1640266. EDGAR lists every VYGR filing under that number.
Ask anything about VYGR
The research agent reads VYGR's filings, financials, insider trades and 13F holders, then answers with sources.